Podium to Practice: Chicago 2026 – GU: NEXUS-1
OR
Studies / Trials Discussed
4508 – Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
4508 – Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.